ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Priothera raises $35 million for leukemia therapy

by Ryan Cross
October 17, 2020 | APPEARED IN VOLUME 98, ISSUE 40

 

09840-buscon15-mocra.jpg

Priothera has raised about $35 million in series A financing to develop drugs for acute myeloid leukemia (AML). The Dublin-based company will use the funds to test mocravimod in a clinical trial of people with AML who are also receiving allogeneic stem cell transplants. Mocravimod is intended to reduce the risk of graft versus host disease and boost the efficacy of the stem cell transplant by targeting sphingosine-1-phosphate receptors. Priothera acquired mocravimod from Kyorin Pharmaceutical, which had licensed it to Novartis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment